Samsung Biologics is a leading contract development and manufacturing organization (CDMO) specializing in biopharmaceutical production. The company operates large-scale facilities for manufacturing biologics—complex drugs derived from living cells—on behalf of global pharmaceutical companies. As one of the world's largest biomanufacturers by capacity, Samsung Biologics serves as a critical partner for drug developers seeking outsourced production capabilities.
[TRANSLATION NOTE] Specific business segment details are derived from the company name and standard CDMO operations, as detailed segment breakdowns were not included in the financial data provided.
Samsung Biologics demonstrates robust growth momentum. Revenue increased 23.1% year-over-year to KRW 4,547 billion in 2024 (fiscal year 14) from KRW 3,695 billion in 2023 (fiscal year 13), continuing strong expansion from KRW 3,001 billion in 2022.
Operating profit reached KRW 1,320 billion in 2024, up 18.5% from KRW 1,114 billion in 2023, yielding an operating margin of 29.0% (down slightly from 30.1% the prior year). Net income grew 26.3% to KRW 1,083 billion in 2024 from KRW 858 billion in 2023. Retained earnings climbed 27.1% to KRW 5,087 billion from KRW 4,003 billion.
The company maintains a conservative balance sheet with total assets of KRW 17,336 billion against total liabilities of KRW 6,432 billion, producing a debt-to-equity ratio of approximately 0.59. Total equity strengthened to KRW 10,905 billion in 2024 from KRW 9,830 billion in 2023. Non-current assets increased significantly to KRW 11,818 billion, suggesting ongoing capacity expansion investments.
Paid-in capital remains steady at KRW 177.9 billion across all three reporting periods. Samsung Biologics is majority-owned by Samsung Group affiliates, with Samsung C&T and Samsung Electronics holding controlling stakes.
[TRANSLATION NOTE] Specific foreign ownership percentage data was not included in the financial statements provided. Detailed shareholder composition would typically appear in separate disclosure documents.
Client Concentration Risk: As a CDMO, Samsung Biologics likely derives significant revenue from a limited number of large pharmaceutical clients. Loss of a major contract or delays in client drug approvals could materially impact revenue.
Capital Intensity and Utilization: The substantial non-current asset base (KRW 11.8 trillion) reflects heavy capital investment in manufacturing facilities. Any slowdown in capacity utilization due to market oversupply or reduced biosimilar demand could pressure margins and return on invested capital.
Samsung Biologics offers exposure to the growing biologics outsourcing market with strong revenue growth and solid profitability, though margin compression and significant capital deployment warrant monitoring amid evolving CDMO competitive dynamics.
⚠️ This profile is AI-generated from DART filings. Quantitative data is reliable. Qualitative summaries should be verified against original Korean filings for investment decisions.